What is the mechanism of action of leukotriene modifiers?

Leukotriene modifiers work primarily by blocking the action or production of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction, mucus secretion, and airway inflammation in conditions such as asthma and allergic rhinitis. By inhibiting the effects of leukotrienes on the airway tissues, these medications help relieve symptoms such as bronchospasm and inflammation. This action reduces airway hyperreactivity and improves overall respiratory function.

Leukotrienes are produced in response to allergens and other stimuli, leading to constriction of the bronchial smooth muscles. By blocking these mediators, leukotriene modifiers prevent the onset of bronchoconstriction and lessen the inflammatory response that can exacerbate asthma symptoms. This makes them effective in managing chronic asthma and preventing exercise-induced bronchospasm.

While other options mention actions related to inflammatory mediators or receptor activities, they do not accurately describe the specific mechanism by which leukotriene modifiers exert their therapeutic effects in the management of respiratory conditions.